Inhibition of heregulin mediated MCF-7 breast cancer cell growth by the ErbB3 binding protein EBP1
- 1 July 2008
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 265 (2) , 298-306
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R01 CA76047, R21 088882-01)
- School of Medicine, University of Maryland (R01 CA76047, R21 088882-01)
This publication has 33 references indexed in Scilit:
- Loss of Nrdp1 Enhances ErbB2/ErbB3–Dependent Breast Tumor Cell GrowthCancer Research, 2006
- Identification of Ebp1 as a component of cytoplasmicbcl-2mRNP (messenger ribonucleoprotein particle) complexesBiochemical Journal, 2006
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survivalCancer, 2005
- Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2Oncogene, 2003
- The ErbB receptors and their role in cancer progressionExperimental Cell Research, 2003
- Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1Oncogene, 2002
- Regulation of Akt/PKB Activation by Tyrosine PhosphorylationJournal of Biological Chemistry, 2001
- Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cellsOncogene, 1999
- Neu Differentiation Factor/Neuregulin Isoforms Activate Distinct Receptor CombinationsJournal of Biological Chemistry, 1996